Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor‐associated macrophage phenotype. Issue 1 (24th January 2022)
- Record Type:
- Journal Article
- Title:
- Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor‐associated macrophage phenotype. Issue 1 (24th January 2022)
- Main Title:
- Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor‐associated macrophage phenotype
- Authors:
- Boibessot, Clovis
Molina, Oscar
Lachance, Gabriel
Tav, Christophe
Champagne, Audrey
Neveu, Bertrand
Pelletier, Jean‐François
Pouliot, Frédéric
Fradet, Vincent
Bilodeau, Steve
Fradet, Yves
Bergeron, Alain
Toren, Paul - Abstract:
- Abstract: Tumor‐associated macrophages (TAMs) support tumor progression within the tumor microenvironment (TME). Many questions remain as to the origin, development, and function of TAMs within the prostate TME. Evaluation of TAMs in prostate cancer (PCa) patients identified the immunosuppressive TAM marker CD163 in adjacent normal epithelium as an independent predictor of metastases or PCa death. Flow cytometry analyses identified prostate TAMs as frequently expressing both proinflammatory M1 (CCR7+) and immunosuppressive M2 (CD163+) markers. In vitro, we demonstrate PCa cells similarly subvert human M1 macrophages toward a mixed M1/M2 macrophage phenotype favoring tumor growth. Further the cytokine milieu‐induced transition between immunosuppressive M2 to proinflammatory M1 (M2→M1) macrophages is abrogated by the presence of PCa cells. RNA sequencing suggests alterations in chemokine expression in prostate TAMs due to the presence of PCa cells. Together, our results suggest that prostate TAMs originate from inflammatory infiltrating macrophages, which are then reprogrammed mainly by PCa cells, but also the cytokine milieu. A better understanding of this subversion of macrophages within the prostate may lead to novel treatment strategies. Abstract : Our results demonstrate that mixed inflammatory and immunosuppressive macrophages found in the prostate develop because of prostate cancer contact. The presence of these macrophages in adjacent normal epithelium portends worseAbstract: Tumor‐associated macrophages (TAMs) support tumor progression within the tumor microenvironment (TME). Many questions remain as to the origin, development, and function of TAMs within the prostate TME. Evaluation of TAMs in prostate cancer (PCa) patients identified the immunosuppressive TAM marker CD163 in adjacent normal epithelium as an independent predictor of metastases or PCa death. Flow cytometry analyses identified prostate TAMs as frequently expressing both proinflammatory M1 (CCR7+) and immunosuppressive M2 (CD163+) markers. In vitro, we demonstrate PCa cells similarly subvert human M1 macrophages toward a mixed M1/M2 macrophage phenotype favoring tumor growth. Further the cytokine milieu‐induced transition between immunosuppressive M2 to proinflammatory M1 (M2→M1) macrophages is abrogated by the presence of PCa cells. RNA sequencing suggests alterations in chemokine expression in prostate TAMs due to the presence of PCa cells. Together, our results suggest that prostate TAMs originate from inflammatory infiltrating macrophages, which are then reprogrammed mainly by PCa cells, but also the cytokine milieu. A better understanding of this subversion of macrophages within the prostate may lead to novel treatment strategies. Abstract : Our results demonstrate that mixed inflammatory and immunosuppressive macrophages found in the prostate develop because of prostate cancer contact. The presence of these macrophages in adjacent normal epithelium portends worse long‐term clinical outcomes for prostate cancer patients, highlighting the importance to develop effective strategies against their development. … (more)
- Is Part Of:
- Clinical and translational medicine. Volume 12:Issue 1(2022)
- Journal:
- Clinical and translational medicine
- Issue:
- Volume 12:Issue 1(2022)
- Issue Display:
- Volume 12, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 12
- Issue:
- 1
- Issue Sort Value:
- 2022-0012-0001-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2022-01-24
- Subjects:
- CD163 -- immunosuppression -- macrophages -- phenotype -- prostate cancer
Clinical medicine -- Periodicals
Medicine, Experimental -- Periodicals
Medical innovations -- Periodicals
Molecular biology -- Periodicals
Pathology, Molecular -- Periodicals
616.027 - Journal URLs:
- https://onlinelibrary.wiley.com/loi/20011326 ↗
http://www.clintransmed.com/content ↗
http://www.biomedcentral.com/journals/#C ↗
http://www.springer.com/gb/ ↗ - DOI:
- 10.1002/ctm2.581 ↗
- Languages:
- English
- ISSNs:
- 2001-1326
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21224.xml